Linfomas del tracto gastrointestinal: una enfermedad neoplásica del subdesarrollo / Gastrointestinal lymphomas: malignant disease of under development

Cuatrocientos cincuentaiocho de los 3,495 casos de linfoma maligno registrados entre los años 1965 y 1992 en el Instituto de Enfemedades Neoplásicas, correspondieron a Linfomas del Tracto Gastrointestinal. Esta es una de las series de linfoma del TGI más grande entre las reportadas por hospitales de cáncer, y sugiere que esta rara patología es relativamente frecuente en nuestro medio. El análisis de esta casuística muestra una mayor frecuencia relativa de la localización en el intestino delgado de esta serie comparte algunas características con el linfoma de la enfermedad inmunoproliferativa del intestino delgado descrita en las poblaciones jóvenes y pobres del Mediterraneo. La enfermedad confinada a la viscera (estadíos I y II) es curable por cirugía en 0 por ciento de casos. La enfermedad avanzada incompletamente resecada puede beneficiarse con quimioterapia complementaria. La enfermedad irresecable quirurgicamente puede ser tratada con quimioterapia complementaria de inducción sin que el riesgo de perforación o hemorragia sea prohibitivo el 50 por ciento de los casos inoperables tratados con quimioterapia alcanzaron sobrevidas a 5 y 10 años libres de recidiva de la enfermedad

Malignant lymphoma of the gastrointestinal tract and mesentery. A clinico-pathologic study of the significance of histologic classification. NHL Study Group of the Comprehensive Cancer Center West.

A series of 92 malignant lymphomas of the gastrointestinal tract and mesentery obtained from a population-based registry was studied to assess whether the newly defined concept of mucosa-associated lymphoma has clinical relevance. The cases were grouped according to localization; gastric, intestinal, and mesenteric lymphoma. All cases were reviewed histologically, graded according to the Working Formulation, and reclassified according to the Kiel classification, which was modified to include the categories low- and high-grade mucosa-associated lymphoma. Clinical data, as well as staging and follow-up data, were related to both the original diagnosis and the diagnosis after reclassification. The results showed that the distribution of the types of lymphoma is related to site: centroblastic lymphoma was predominant in the stomach, lymphoblastic in the bowel, and follicular centroblastic-centrocytic in the mesentery. Gastrointestinal lymphoma was disseminated in approximately 50% of the patients at presentation. Survival analysis revealed that classification according to the original Kiel classification and grading according to the Working Formulation provided important prognostic information, whereas introduction of mucosa-associated lymphoma as an entity did not. It was concluded that modification of current classifications to include a separate category for mucosa-associated lymphoma is not useful.